The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical ...

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical ...

Pro-Lab Diagnostics has launched a high quality immunoassay for rapid and accurate screening of patients with suspected Clostridium difficile infection. The Prolisa™ C. difficile GDH (glutamate ...

Thu, January 5, 2012 at 2:30 PM UTC ImmunoCard C. difficile GDH is geared to detect a common antigen, known as Glutamate dehydrogenase (“GHD”), produced by the toxigenic and non-toxigenic forms of C.

Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test. The ImmunoCard C. difficile GDH test has already ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening ...

A two-step approach for diagnosing C. difficile has been found to be both cost-effective and significantly more sensitive than other methods in use AbstractLewis, J. (2009) Exploring the accuracy and ...

Clostridium difficile infection is the leading cause of gastroenteritis-associated death and has become the most common cause of health care–associated infections in US hospitals. For long-term care ...

CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc. (NASDAQ:VIVO) is pleased to announce the launch of a new Clostridium difficile rapid test, ImmunoCard C. difficile GDH. This assay detects the ...